Previous study demonstrated that apatinib inhibits VEGF-mediated cell migration and invasion of CCA cell lines [12], and apatinib promotes apoptosis in intrahepatic cholangiocarcinoma [24], which highlight the potential clinical utility of apatinib in BTC. This evidence concerns the gene VEGFA and intrahepatic cholangiocarcinoma.